Search

"Ocular AEs reported during the treatment of AD with dupilumab have been increasing sharply, and were proposed to be under the definition "dupilumab induced ocular surface disease" (DIOSD) by Zirwas et al", commented the authors. Ocular adverse events (AEs) have been increasingly reported after wider use of the monoclonal antibody dupiliumab for the treatment of atopic dermatitis (AD), say authors of a bibliometric analysis published in I Frontiers in Medicine i . A search of the Web of Science database identified 138 articles (or letters) published between 2016 and August 2020 which reported ocular AEs during the treatment of AD with dupilumab. [Extracted from the article]